Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis
Zhaolun Cai, Chunyu Liu, Chen Chang, Chaoyong Shen, Yuan Yin, Xiaonan Yin, Zhiyuan Jiang, Zhou Zhao, Mingchun Mu, Dan Cao, Lingli Zhang, Bo Zhang
Topics & Concepts
TolerabilityMedicineDiscontinuationOlaparibAdverse effectPARP inhibitorPlaceboInternal medicineOncologyRandomized controlled trialPharmacologyPoly ADP ribose polymerasePathologyBiochemistryAlternative medicinePolymeraseGeneChemistryPARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesEconomic and Financial Impacts of Cancer